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To determine the types of human papillomaviruses (HPV) in northern Morocco, infor-
mation which is needed for the design and use of HPV vaccines, we have analysed 129
cervical biopsies from this region. In our study, 91 cases were HPV positive, 45 cases had
HPV-16 DNA, and 20 cases had HPV-18 DNA. This distribution of virus type was similar
in inflammatory cervical lesions and in invasive cervical carcinomas. In conclusion, the
HPV type distribution in Morocco is similar to that in other African Mediterranean
countries, where the proportion of HPV-18 cases is significantly higher than in Europe.
Determination of virus-type distribution is essential for vaccination programs.
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I N T R O D U C T I O N
Clinical and epidemiological studies have shown
that human papillomaviruses (HPV) play a major
role in the development of different types of cer-
vical lesions, and are therefore considered as the
major infectious aetiological agents of genital
lesions and cancers [1]. HPV are strictly epithelio-
tropic viruses infecting skin or mucosal surfaces,
and displaying a very high selectivity for the
specific epithelium infected. To date, more than
85 HPV types have been characterized [2]. Genital
HPV types are associated with a wide spectrum of
morphological lesions [3]. HPV-6, -11, -42, -43 and
-44 are associated with benign lesions (condylo-
mas), whereas HPV-31, -33, -35, -51, -52 and -58 are
detected more frequently in low squamous intra-
epithelial lesions (LSIL) and HPV-16 and -18 are
predominant in high grade SIL (HSIL) and inva-
sive carcinoma [4]. HPV-16 and HPV-18 DNA
sequences are frequently integrated into the gen-
ome of cervical cancer cells, and this integrated
HPV DNA is an indicator of poor prognosis [5,6].
The prevalence of HPV DNA in cervical lesions
ranges from 25 to 90%. HPV-16 accounts for the
highest proportion, followed by HPV-18, HPV-45
and HPV-31, but their incidence varies depending
on the country [7].
The lack of standardized detection methods
represents a major problem for monitoring HPV
in developing countries, where the problem is
most acute. In the absence of an international
consensus concerning detection methods, HPV
infections are difficult to diagnose. However, sen-
sitive and specific methods, based on the detection
of HPV DNA, are available. Among them, the
polymerase chain reaction (PCR) technique is
the method of choice for epidemiological studies
[8]. However, PCR is a major technological
advance not readily available in developing coun-
tries.
In a previous study, it was reported that HPV-16
is the most frequent type in Morocco, followed by
HPV-18 [9]. Thus, we focused our interest on these
two types. In Morocco, invasive cervical cancer is
the primary cause of cancer deaths in women and
represents a major public health problem. At the
hospital-based cancer registry of the Institut
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National d’Oncologie (INO) in Rabat, the number
of cases of mostly advanced invasive carcinomas
exceeds 500 per year [9]. The present study aimed
to determine the type of HPV DNA present in
inflammatory cervical lesions and invasive cervi-
cal carcinomas in patients from northern Morocco.
Knowledge of the HPV types circulating in devel-
oping countries is very important for the future
application of prophylactic vaccines.
P A T I E N T S A N D M E T H O D S
To determine the presence of HPV in cervical
pathology in Rabat, we set up a PCR laboratory.
Cervical biopsy specimens were obtained from 129
consecutive patients coming for consultation and
treatment to the INO in Rabat, Morocco, between
June 1999 and June 2000. Samples were obtained
with informed consent according to INO policy [9].
The patients came from the northern area of Mor-
occo, from Rabat to the Mediterranean coast,
where half the population of the country is located.
This is the geographical area covered by INO.
There was no concentration of cases from any
specific region in this area. There was no case
selection because we wanted to determine what
was present in the cancer patients in general. Two
pathologists independently analysed all biopsies
and sections were sent for molecular analysis to
the Molecular Biology Unit of CNESTEN in Rabat.
Lesions were classified according to FIGO (Inter-
national Federation of Gynecoloy and Obstetrics)
stages [10]. Therefore, they were enrolled as con-
secutive cases for which biopsy material was avail-
able. Only material from patients who had not yet
been treated by radiation therapy was used.
DNA was extracted from paraffin-embedded
sections (5–10 mm) with xylene and ethanol. The
remaining cellular pellet was resuspended in
digestion buffer (20 mM Tris–HCl pH 8.0, 20 mM
ethylenediaminetetraacetic acid and 0.3 M, 0.5%
sodium dodecyl sulphate and 0.1 mg/mL protei-
nase K) and incubated overnight at 37 8C. DNA
isolation was performed by phenol–chloroform
extraction and ethanol precipitation, and was
resuspended in 50 mL of sterile distilled water [11].
The amplification reaction was performed in a
final volume of 50 mL containing 50 pmol of each
primer (MY09 and MY11), 200 mM each dNTP,
0.625 units Taq DNA polymerase (Amersham Bios-
ciences, Little Chalfont, UK) and 3 mL of DNA
sample in 1 Taq polymerase buffer. The mixture
was first denatured at 94 8C for 7 min. Then, 35
cycles of PCR were performed by denaturation at
94 8C for 30 s, primer annealing at 52 8C for 10 min,
and primer extension at 72 8C for 90 s. At the end of
the last cycle, the mixture was incubated at 72 8C
for 7 min. The PCR was performed in a thermo-
cycler Amplitron II Thermolyne model (Barnstead
Thermolyne Corporation, SYBRON INTERNA-
TIONAL, Milwaukee, WI, USA). For every reac-
tion, a negative control in which the DNA template
was omitted from the amplification mixture, and a
positive control were included. Aliquots of 10 mL
of the PCR product were analysed by electrophor-
esis through a 1.2% agarose gel. The lengths of the
amplified viral L1 fragment was the expected
450 base pairs (not shown), and to avoid problems
associated with the use of HPV consensus primers
[12], PCR products were transferred to a Hybond-
Nþ membrane (Amersham Biosciences) and the
membrane was hybridized with either a consensus
HPV probe, or HPV-16- and HPV-18-specific
probes [13]. The signal in the blots was detected
using the DIG luminescence detection kit (Amer-
sham Biosciences) according to the manufacturer’s
instructions.
R E S U L T S
The histopathological analysis of the cases
detected inflammatory lesions in 34 cases (26%),
low grade cervical intraepithelial neoplasia (CIN)
in eight cases (6%), and high grade CIN and
invasive carcinomas in 87 cases (67%). An addi-
tional 20 cases with normal squamous epithelium
were studied. It is important to draw attention to
the disproportionately high number of advanced
cases: 67 samples already corresponded to inva-
sive carcinomas in stages II to IV, which are unu-
sual in European or North American countries. In
Morocco cervical lesions are usually diagnosed in
very advanced stages of the disease.
HPV detection and typing were always per-
formed in coded samples. The code was opened
to identify the histopathological grade corre-
sponding to each sample after the HPV result
was available.
The results obtained for the 129 consecutive
specimens are summarized in Table 1. HPV
DNA was detected in 91 biopsy samples. Our
results showed that HPV-16 was by far the most
frequent type: it was found in 45 of the cases (49%)
whereas HPV-18 was detected in only 20 cases
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(22%). Two specimens had a double infection with
HPV-16 and HPV-18, and 27 HPV-positive cases
(30%) corresponded to other viral types that were
not identified. The relative distribution of HPV-16
and HPV-18 in inflammatory lesions was similar to
that in invasive cervical carcinomas (Table 1).
D I S C U S S I O N
In Morocco, as in other developing countries, the
lower social conditions, the average age at first
intercourse, the high rate of parity and the lack of
primary care in the health systems are important
risk factors for the rate of cervical cancer [9]. The
prevalence of HPV-16 in invasive cervical carci-
nomas from northern Morocco represented 49% of
the HPV-positive specimens. This value is some-
what lower than the results found in other devel-
oping countries: Latin America (54.4%), Thailand
(59.3%) and India (64%). In some European coun-
tries, the HPV-16 prevalence was higher, such as
78.3% in Poland and 76.5% in Germany [1].
In our study, HPV-18 was found in 22% of HPV-
positive specimens, which is more than twice the
level previously reported in Moroccan samples [9].
The relative proportion of HPV-16/HPV-18 in this
study is similar to that for Africa and other coun-
tries such as Algeria, but is different from that in
other Mediterranean countries in Europe, which
have a higher proportion of HPV-16 cases [1]. We
also found a similar virus-type distribution in
inflammatory lesions and in cervical carcinomas
(Table 1). These inflammatory lesions might be
precursors of future cervical carcinomas, but this
point will only be established after a follow-up of
these patients for several years. The persistence of
HPV DNA is an indicator of possible cervical
cancer development in the future [14]. Thus the
detection of high-risk HPV types in women is an
important risk factor that allows identification of
those women who should be monitored more
closely [15], rather than concentrating limited
medical resources on patients with lesions that
will spontaneously regress. The age of determina-
tion may vary depending on the age structure of
the population of a specific country.
The detection of a number of HPV-negative
cases is a reality that must be fully recognized,
instead of trying to attribute these cases to either a
yet unknown HPV type or technical problems
(both arguments are difficult to justify today).
Cervical cancer shares with all other tumours
the same biological characteristics regarding
alterations in cell growth and division, apoptosis,
cell life span, angiogenesis, tissue invasion and
metastasis [16]; therefore cervical epithelial cells
should also be able to undergo the same malignant
processes as epithelial cells from other organs,
which are independent of HPV presence. These
properties have a genetic origin which is not HPV
related, and that has been extensively studies in
cervical carcinoma, sharing many characteristics,
such as common loss of heterozygosity (LOH),
with other tumors as expected [17]. However,
HPV persistence is a major predisposing factor
for tumor development in cervical cells containing
HPV DNA [14,18], hence its detection in such a
very high number of invasive cervical carcinomas.
In many different studies, the number of negative
cases ranges from 5 to 25%. Thus we can reason-
ably assume that approximately 10% of the cases
are HPV negative, and therefore the role of per-
sistent HPV will be to increase, by at least an order
of magnitude, the likelihood of developing cervi-
cal carcinoma.
The magnitude of the public health problem
represented by cervical carcinoma in develop-
ing countries might be even bigger in the future,
Table 1 Distribution of HPV types in consecutive cervical biopsies from northern Morocco
HPV type
Lesion No. of cases HPV negative HPV positive HPV-16 HPV-18 Other
Inflammatory lesions 34 9 25 (100) 10 (40) 6 (24) 9 (36)
Low grade CIN 8 4 4 (100) 4 (100)
High grade CIN and invasive 87 25 62 (100) 31 (50) 14 (23) 19 (31)
carcinomas (ISC and ADC)
Total 129 39 91 (100) 45 (49) 20 (22) 28 (31)
CIN, cervical intraepithelial neoplasia; ISC, invasive squamous cell carcinoma; ADC, adenocarcinoma.
Two ISC cases were HPV-16- and HPV-18-positive and are counted in both columns. In parentheses are the percentage
values.
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considering that the population of these countries
is relatively young compared to that of developed
countries. This means that if public health mea-
sures are not taken in order to identify the high-
risk subpopulation, the burden of cervical carci-
noma in these countries will increase considerably.
HPV is currently the target of many vaccine devel-
opment projects for prevention and therapy of
cervical carcinoma [19]. The knowledge of HPV
types circulating in developing countries is an
essential component for the future application of
prophylactic vaccines that aim to reduce the bur-
den of cervical carcinoma [19,20]. In developing
countries the control of HPV by vaccination is
likely to be a more effective and practical approach
than the implementation of regular and periodic
cytological screening. Currently prophylactic vac-
cines are based on HPV-16 [20,21]. The virus-type
distribution varies among different regions of the
world, which means that there will always be a
proportion of potential cases that will not be pre-
vented. It is known that vaccination using virus-
like particles against L1 from HPV-16 induces a
significant immune response, which does not red-
uce the likelihood of acquiring another virus type
[22]. Furthermore, the persistence of virus types not
targeted for vaccination might represent a new pro-
blem with time [23], since they might occupy the
biological niche left empty by the vaccine, and a
previously low-frequency malignant type might
eventually become dominant and widespread.
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